2 C
New York
Wednesday, February 1, 2023

Is CymaBay Therapeutics Inc. (NASDAQ: CBAY) Still On The Rise?

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for CymaBay Therapeutics Inc. (CBAY) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.03, or -0.50%, to $5.93. The CymaBay Therapeutics Inc. has recorded 25,651 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $5.96 and fluctuated between $6.32 as its day high and $5.87 as its day low. The current market capitalization of CymaBay Therapeutics Inc. is $486.99M. A total of 3.26 million shares were traded on the day, compared to an average of 514.82K shares.

Insider trades can also provide insight into a stock’s future direction. During the recent three months, CBAY has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 2 BUYs and 0 SELLs from insiders. Insiders purchased 71,301 shares during that period but sold 0.

In the most recent transaction, Shah Sujal bought 51,301 shares of CBAY for 1.95 per share on Jun 06. After the transaction, the Chief Executive Officer now owns 171,301 company shares. In a previous transaction on Jan 19, KIM DENNIS D bought 20,000 shares at 3.04 per share. CBAY shares that Chief Medical Officer owns now total 20,000.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CBAY in the last 3 months, the mean price target is $10.00 with high estimates of $14.00 and low estimates of $8.00. In terms of 52-week highs and lows, CBAY has a high of $6.41 and a low of $1.67.

As of this writing, CBAY has an earnings estimate of -$0.3 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.25 per share and a lower estimate of -$0.34. The company reported an EPS of -$0.32 in the last quarter, which was -3.20% lower than expectations of -$0.31.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 9 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CBAY is Overweight with a score of 5.00. A total of 9 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles